A group of proteins known as toll-like receptors (TLRs) are essential components of the innate immune system. They are single, membrane-spanning, non-catalytic receptors that recognize structurally conserved molecules derived from microbes and are typically expressed in sentinel cells like macrophages and dendritic cells. Once these microbes have gotten past physical barriers like the skin or mucosa of the gastrointestinal tract, TLRs recognize them and trigger immune cell responses.
TLR1 through TLR13 are among the TLRs, along with TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13. Toll-Like Receptors (TLRs) are involved in both the detection of endogenous danger signals and the early innate immune response to encroaching pathogens. TLRs are homologs of the Drosophila Toll protein, which was found to be crucial for defense against microbial infection. They are evolutionarily conserved receptors. TLRs identify pathogen-associated microbial patterns (PAMPs), which are only expressed by microbial pathogens and are highly conserved structural motifs.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V5846 | SM-324405 | 677773-91-0 | SM-324405 (SM324405; SM 324405) is a novel and potent TLR7 (toll-like receptor 7) agonist designed by introducing the antedrug concept with reduced systemic activity. |
|
V74348 | Stepharine | 2810-21-1 | Stepharine is a naturally occurring alkaloid that directly targets TLR4 (TLR4 inhibitor) and binds to the TLR4/MD2 complex. |
|
V74339 | Sulfo-ara-F-NMN (CZ-48) | 1374663-29-2 | Sulfo-ara-F-NMN (CZ-48) is an analog of nicotinamide mononucleotide (NMN). |
|
V81521 | TAT-CIRP | TAT-CIRP is a small peptide that refers to the trans-transactivating (Tat) cold-inducible RNA-binding protein. | |
|
V74369 | Tilsotolimod | 1948266-37-2 | Tilsotolimod is a TLR9 agonist that has shown anti-tumor effects in preclinical models. |
|
|
V74363 | Tilsotolimod sodium | 2089768-67-0 | Tilsotolimod is a TLR9 agonist that has shown anti-tumor effects in preclinical models. |
|
V16506 | TLR2-IN-C29 (C29 ) | 363600-92-4 | TLR2-IN-C29 is an inhibitor of TLR2/1 and TLR2/6 signaling. |
|
V37647 | TLR4-IN-C34 | 40592-88-9 | TLR4-IN-C34 is an orally bioactive TLR4 inhibitor that improves systemic inflammation in models of endotoxemia and necrotizing enterocolitis. |
|
V76410 | TLR4-IN-C34-C2-amide-C6-OH | TLR4-IN-C34-C2-amide-C6-OH is a linker containing the TLR4 inhibitor TLR4-IN-C34. | |
|
V74345 | TLR4-IN-C34-C2-COOH | 1159408-54-4 | TLR4-IN-C34-C2-COOH is a linker containing the TLR4 inhibitor TLR4-IN-C34. |
|
V74364 | TLR4agonist-1 | 2374139-51-0 | TLR4 agonist-1 (compound 17a) is a potent agonist of Toll-like Receptor 4 (TLR4) and induces MIP-1β production in RAW 264.7 and MM6 cells. |
|
V81595 | TLR4agonist-1TEA | TLR4 agonist-1 (TEA) (compound 17a) is a potent agonist of Toll-like Receptor 4 (TLR4) and induces MIP-1β production in RAW 264.7 and MM6 cells. | |
|
V51764 | TLR7 agonist 11 | 2389988-36-5 | TLR7 agonist 11 is an analogue of purine nucleoside. |
|
V51762 | TLR7 agonist 12 | 2389988-47-8 | TLR7 agonist 12 (Example 20) is a TLR7 agonist and an analogue of purine nucleoside. |
|
V74377 | TLR7 agonist 14 | 2832199-45-6 | TLR7 agonist 14 (compound 17b) is a potent TLR7 agonist/activator with EC50 of 59 nM. |
|
V74368 | TLR7 agonist 16 | 2832199-56-9 | TLR7 agonist 16 (compound 16d) is a potent TLR7 agonist/activator with EC50 of 59 nM. |
|
V4750 | TLR7 agonist 2 | 1642857-69-9 | TLR7 agonist 2 is a novel, oral, potent and selective agonist of Toll-like Receptor 7(TLR7) with antiviral activity. |
|
V51761 | TLR7 agonist 5 | 2380231-67-2 | TLR7 agonist 5 (compound IIb-11) is a potent TLR7 agonist/activator with EC50 of about 4 nM. |
|
V51758 | TLR7 agonist 6 | 2380231-86-5 | TLR7 agonist 6 (compound IIb-19) is a potent TLR7 agonist/activator with EC50=1.0 nM. |
|
V51759 | TLR7 agonist 7 | 2380231-77-4 | TLR7 agonist 7 (compound IIb-26) is a potent TLR7 agonist/activator with EC50 of about 4 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
